# Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

> **NCT01449357** · PHASE2 · WITHDRAWN · sponsor: **Genmab**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** zalutumumab

## Key facts

- **NCT ID:** NCT01449357
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial never initiated
- **Last updated:** 2011-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01449357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01449357, "Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01449357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*